[Weight loss treatment of obese type 2 diabetic patients]
- PMID: 16403345
[Weight loss treatment of obese type 2 diabetic patients]
Abstract
Weight loss of several kilograms improves glycaemic control and the lipid profile and reduces blood pressure. A consultation with a clinical dietician who is educated in behaviour therapy can, for many patients, induce a weight loss of 5-10%. The use of orlistat and sibutramine has been shown to increase weight loss by about 2-6 kilograms. A very-low-calorie diet (VLCD) promotes faster and greater weight loss. Surgical treatment of obesity results in considerable weight loss and often normalisation of blood glucose levels. Except for surgically treated patients, most patients begin to regain the weight lost four to six months after the start of the change in diet.
Similar articles
-
Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.Chang Gung Med J. 2007 Nov-Dec;30(6):538-46. Chang Gung Med J. 2007. PMID: 18350737 Clinical Trial.
-
Management of obesity in NIDDM (non-insulin-dependent diabetes mellitus).Singapore Med J. 1998 Aug;39(8):380-4. Singapore Med J. 1998. PMID: 9844503 Review.
-
Serum retinol-binding protein 4 is not increased in obesity or obesity-associated type 2 diabetes mellitus, but is reduced after relevant reductions in body fat following gastric bypass.Clin Endocrinol (Oxf). 2008 Aug;69(2):208-15. doi: 10.1111/j.1365-2265.2007.03156.x. Epub 2007 Dec 10. Clin Endocrinol (Oxf). 2008. PMID: 18081728 Clinical Trial.
-
The effects of orlistat treatment interruption on weight and associated metabolic parameters.Prague Med Rep. 2006;107(4):394-400. Prague Med Rep. 2006. PMID: 17402552
-
Effects and clinical potential of very-low-calorie diets (VLCDs) in type 2 diabetes.Diabetes Res Clin Pract. 2009 Sep;85(3):235-42. doi: 10.1016/j.diabres.2009.06.002. Epub 2009 Jun 27. Diabetes Res Clin Pract. 2009. PMID: 19560834 Review.